Adjunctive Linezolid for the Treatment of Tuberculous Meningitis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

July 5, 2023

Study Completion Date

December 4, 2023

Conditions
Tuberculosis, Meningeal
Interventions
DRUG

LZD

LZD 1200 mg daily

DRUG

High dose RIF

RIF 35 mg/kg/day

DRUG

Standard dose RIF

RIF 10 mg/kg/day

Trial Locations (1)

Unknown

Masaka Regional Referral Hospital/MRC UVRI Uganda Research Unit on AIDS, Masaka

All Listed Sponsors
collaborator

MRC/UVRI and LSHTM Uganda Research Unit

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Fogarty International Center of the National Institute of Health

NIH

lead

University of California, San Francisco

OTHER